UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 3, 2011
COMPLETE GENOMICS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-34939 | 20-3226545 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) |
2071 Stierlin Court
Mountain View, California 94043
(Address of principal executive offices, including Zip Code)
Registrants telephone number, including area code: (650) 943-2800
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On March 3, 2011, at a meeting of the Compensation Committee (the Committee) of the Board of Directors of Complete Genomics, Inc. (the Company), the Committee approved discretionary cash bonuses to certain of the Companys executive officers for 2010:
Executive Officer and Position |
Discretionary Bonus Amount |
|||
Ajay Bansal, Chief Financial Officer |
$ | 70,000 | ||
Bruce Martin, Senior Vice President of Product Development |
$ | 70,000 | ||
Mark J. Sutherland, Senior Vice President of Business Development |
$ | 28,000 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 9, 2011 | COMPLETE GENOMICS, INC. | |||||
By: | /s/ Ajay Bansal | |||||
Ajay Bansal | ||||||
Chief Financial Officer |